{
  "pmcid": "12061372",
  "sha256": "c4cfb35b0efa1fdf146132c2889380f744c81880f9ea434018f368b4140979da",
  "timestamp_utc": "2025-11-09T15:29:12.240442+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.588266475644701,
    "reading_ease": 35.88851388582765,
    "word_count": 349
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "two phase 3, randomized, double-blind, placebo- and active-controlled trials"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "participants were randomized"
      },
      "Participants": {
        "score": 2,
        "evidence": "adults with moderate-to-severe acute pain on the verbal categorical rating scale and 4 or greater on the numeric pain rating scale after abdominoplasty (n = 1,118) or bunionectomy (n = 1,073)"
      },
      "Intervention": {
        "score": 2,
        "evidence": "participants were randomized to suzetrigine (100 mg, then 50 mg every 12 h), hydrocodone bitartrate/acetaminophen (5/325 mg every 6 h), or placebo for 48 h"
      },
      "Objective": {
        "score": 1,
        "evidence": "To evaluate suzetrigine for treatment of acute pain"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was time-weighted sum of the pain intensity difference in numeric pain rating scale from 0 to 48 h (SPID48) versus placebo"
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "participants were randomized"
      },
      "Blinding": {
        "score": 2,
        "evidence": "double-blind"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "n = 1,118) or bunionectomy (n = 1,073)"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The least squares mean difference in SPID48 between suzetrigine and placebo was 48.4 (95% CI, 33.6 to 63.1; P < 0.0001) after abdominoplasty and 29.3 (95% CI, 14.0 to 44.6; P = 0.0002) after bunionectomy"
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar to those seen in postsurgical settings"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}